(NASDAQ: DNLI) Denali Therapeutics's forecast annual revenue growth rate of -10.36% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Denali Therapeutics's revenue in 2024 is $330,531,000.On average, 9 Wall Street analysts forecast DNLI's revenue for 2024 to be $14,022,620,643, with the lowest DNLI revenue forecast at $5,566,409,560, and the highest DNLI revenue forecast at $37,503,684,411. On average, 8 Wall Street analysts forecast DNLI's revenue for 2025 to be $21,931,931,987, with the lowest DNLI revenue forecast at $6,515,204,070, and the highest DNLI revenue forecast at $53,729,768,278.
In 2026, DNLI is forecast to generate $33,807,588,463 in revenue, with the lowest revenue forecast at $1,736,719,783 and the highest revenue forecast at $68,074,405,714.